he impact of the COVID-19 pandemic was palpable throughout the drug development pipeline. Many of the policies, practices, and principles that emerged during 2020 will continue to shape clinical research and drug development practices for years to come. In addition to operational hurdles, COVID-19 also brought us new ethical challenges that will continue to resonate throughout the drug development community.
DIA’s new Bioethics Community recently cosponsored an interactive online conversation with internationally renowned bioethicist Arthur Caplan, cohosted by Bioethics Community Communications Chair Lindsay McNair (WCG) and Bioethics Community Chair Karla Childers (Johnson & Johnson), to discuss bioethical issues that came into new focus in 2020 and respond to audience questions on the topic Clinical Research and Bioethics: Looking at COVID-19 as a Turning Point.
Watch and listen to this webinar (free registration required).
with Arthur Caplan
Drs. William F. and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU Grossman School of Medicine
Former Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine, where he created the Center for Bioethics and the Department of Medical Ethics
Current member of the WHO Ethics and Ebola Working Group
Current member of the University of Pennsylvania’s External Advisory Committee for the Orphan Disease Center
Lifetime Achievement Award from the American Society for Bioethics and Humanities
Internationally recognized expert in pre-approval access and member of numerous committees related to COVID such as the NCAA COVID and Sports Committee; the US Conference of Mayors Group on Sports, Recreation and COVID; the WHO Pre-Approval Access Committee for Drugs and Vaccines for COVID; and The Lancet Commission on Vaccine Hesitancy.